Mit biomedizinischer Forschung schneller zum Patienten: ForTra gGmbH gibt positive Förder-Bilanz bekannt
April 23, 2024 04:00 ET
|
AKAMPION
Lücke zwischen Grundlagenforschung und klinischer Anwendung schließenMehr als 50 Prozent aller geförderten Projekte erhalten Anschlussfinanzierung Bad Homburg v.d. Höhe, 23.04.2024 – Die...
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track Record
April 23, 2024 04:00 ET
|
AKAMPION
Closing the gap between basic research and clinical applicationMore than 50 percent of all funded projects received follow-up funding Bad Homburg v.d. Höhe, Germany, April 23, 2024 - ForTra gGmbH...
Criterium, Inc. Announces Formation of New Oncology Research Consortium for Genito-Urinary Indications
January 26, 2023 09:30 ET
|
Criterium Inc.
SARATOGA SPRINGS, N.Y., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Criterium, Inc., a full-service Contract Research Organization (CRO), is pleased to announce AURIC (Academic Urology Research Investigators...
AnaBios Announces Inaugural Translational Research Conference to Be Held in San Diego
November 08, 2022 09:00 ET
|
AnaBios
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AnaBios today announced the inaugural Translational Research Conference to be held Feb. 27-28, 2023, in San Diego, California. The conference will gather...
Codex DNA Announces Plan to Change Corporate Name to Telesis Bio
October 12, 2022 09:00 ET
|
Codex DNA, Inc.
SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name to...
Codex DNA weitet Anwendung der firmeneigenen Fehlerkorrekturtechnologie aus
October 04, 2022 09:00 ET
|
Codex DNA, Inc.
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), ein Pionier im Bereich automatisierter Tischsysteme für die synthetische Biologie, gab heute die Markteinführung der...
Codex DNA étend l'application de la technologie exclusive de correction des erreurs
October 04, 2022 09:00 ET
|
Codex DNA, Inc.
SAN DIEGO, 04 oct. 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ : DNAY), un pionnier des systèmes de paillasse automatisés de biologie synthétique, a annoncé aujourd'hui le lancement commercial...
Codex DNA Expands Application of Proprietary Error Correction Technology
October 04, 2022 09:00 ET
|
Codex DNA, Inc.
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release of BioXp® Error-corrected...
Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands
September 26, 2022 07:00 ET
|
Codex DNA, Inc.
SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, will showcase its recently released BioXp™ 9600 system at the...
Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation
September 19, 2022 07:00 ET
|
Codex DNA, Inc.
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release and first shipment of the...